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The traditional research and development model of large
pharmaceutical companies is arguably unsustainable in current times. For
example, estimated research and development costs increased as much as
twelve percent over the last year while pharmaceutical sales grew only
seven percent over the same period.1 Current estimates put the price to
develop a new drug and bring it to market between $800 million and $1.5
billion per drug.2 These costs are increasing, driving large pharmaceutical
companies to find more cost-effective research and development models.
One cost-saving initiative is to globalize the system. In particular,
companies have increasingly outsourced the required investigational drug
trials from developed countries in which the drugs would be sold, such as
the United States, to developing countries, such as India.
3
Accordingly, the scope of human drug research and development is
undergoing rapid globalization. Global economic factors and recent
changes in Indian regulations have created a situation that could be
described as a "perfect storm" for a clinical trial outsourcing boom in India.
* J.D. Candidate, 2008, Northwestern University School of Law.
CHARLES W. THURSTON, INSTITUTIONAL INVESTOR SPONSORED REPORT, INVESTING IN
PHARMACEUTICALS: PHARMACEUTICAL COMPANIES STRUGGLE TO KEEP THE PIPELINE
PRESSURIZED 1, (2006), available at http://www.iimagazine.com/images/564/53187
[Investing%20Pharmaceuticals.pdf.
2 Id.
3 Kounteya Sinha, India to Follow US, UK Lead on Trials, TIMES OF INDIA, Oct. 23,
2005, available at 2005 WLNR 17162488.
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Just as India has become the premiere destination for outsourcing the work
of technology call centers and software developers, the country is now
positioned to become the global hotspot of this new outsourcing movement.
India has much to gain from such clinical trial outsourcing. Officials
in India's Health Ministry stated that in 2003 the country earned $70
million in revenue from clinical trials.4 According to estimates, this amount
will grow to $200 million in 2007 and reach $1.5 billion by 2010.5 Despite
the obvious economic benefit, critics decry the practice, positing that it
makes India a "guinea pig to the world.",
6
The controversial practice of U.S. pharmaceutical companies
outsourcing their clinical research to the Indian population raises several
significant questions. For example, are U.S. pharmaceutical companies
evading regulatory controls by outsourcing trials to India rather than
conducting them in the United States? Will the safety and rights of Indian
trial volunteers be protected as well as those of their U.S. counterparts? Is
the Indian population unfairly abused in taking most of the risk of clinical
research but little of the benefit? Lastly, does India deserve its disparaging
nickname of "guinea pig to the world"?
Close oversight of trials and protection of test subjects are necessary in
order to minimize the risks to which human test subjects are exposed, and
to ensure that test subjects understand the risks of participating in drug
research. Even in developed nations, the benefits of human drug research
are only achievable with negative tradeoffs, particularly in the form of risks
to the health of the people involved in the investigational trials. It was
recently reported in the United Kingdom that an investigational drug trial of
a drug meant to treat chronic inflammatory conditions and leukemia instead
left two test subjects fighting for life.7 In total, six of the volunteers fell
seriously ill after the trial.8 One student volunteer in the trial "want[ing] to
make a bit of extra money" was reportedly "left looking like the Elephant
Man." 9 Although this tragic example may be extreme, it is evidence of the
inevitable risk that human test subjects in drug research face, because drug
experimentation is based on an incomplete knowledge of the drug's effects
on the human body. The unfortunate reality of human experimentation
proves the need for regulation of clinical trials to balance scientific progress
with test subject protection.
4 Id.
5 id.
6 Jennifer Kahn, A Nation of Guinea Pigs, WIRED, Mar. 2006, available at http:/www
.wired.com/wired/archive/14.03/indiadrug.html.
7 Scandal of Drugs Trial Guinea Pigs, WESTERN DAILY PRESS, Mar. 16, 2006, at 11,





Further evidence of the need for close regulations is that repeated
stories of abuse pervade the history of human experimentation. One need
only recall the Nazi experiments on concentration camp prisoners during
World War 11 (1939-1945) or the Tuskegee syphilis study (1932-1972).
The lesser known-but equally disturbing-Human Radiation Experiments
began in 1944 and continued until as recently as 1974.10 U.S. government
scientists working on nuclear weapons research projects performed research
to determine the effects of plutonium on humans by experimenting on more
than 4,000 unknowing and non-consenting test subjects." The test subjects
were hospital patients thought to be either terminally ill or have a life
expectancy of less than ten years due to age or chronic disease condition.
2
In some experiments, the scientists injected plutonium into patients,
including a five-year-old child, without even informing them of the contents
of the injection, much less giving them the opportunity to consent to or
reject the procedure. 13 Such tragic tales of abuse shroud the history of
human experimentation and serve as a reminder and an impetus for strong
regulations and protections of human test subjects in human
experimentation and drug research.
Although terrible, the abuses and misfortunes of many test subjects
have contributed to the development of law regarding medical research on
humans. While there are international documents and agreements relating
to human experimentation, the regulation of clinical research is dominated
by legislation on the national level. This Comment will first discuss the
reasons behind the growing trend of outsourcing investigational drug trials
to India. After presenting the relevant background, the Comment will
explain the regulation of clinical trials and protections for test subjects in
the United States. Next, the Comment will explain the regulation of clinical
trials and protections for test subjects in India and compare the regulatory
system there with that in the United States. The Comment will then discuss
pertinent international law and, finally, conclude with a summary and a
discussion of the economic, regulatory, and ethical realities of U.S.
pharmaceutical companies outsourcing clinical research to India.
10 See ADIL E. SHAMOO & DAVID B RESNIK, RESPONSIBLE CONDUCT OF RESEARCH 181-92
(2003) (explaining briefly each of the mentioned atrocities as well as others).




International Law & Business 28:125 (2007)
II. INDIA AS THE GLOBAL HOTSPOT FOR CLINICAL TRIAL
OUTSOURCING
A. Financial and Logistical Factors
The outsourcing of investigational drug trials is fueled by an increase
in logistical and financial problems associated with conducting the trials in
developed countries. 14 It is increasingly difficult and expensive to perform
investigational drug trials in the United States. Logistically, recruitment of
research subjects is slow and costly because the population of potential test
subjects is relatively small and unwilling to volunteer. 15 While the number
of volunteers needed for clinical trials is increasing, the number of
Americans willing to enroll in trials lags. For example, only 1.7% of
eligible cancer patients in the United States enroll in investigational drug
trials.16
The reason for the shortfall has been attributed to the unwillingness of
American patients, and also, more importantly, to the unwillingness of their
doctors to recommend participation. While a primary misunderstanding
for patients is the worry that they may be given a placebo instead of actual
treatment,' 8 doctors are often reluctant to recommend or mention clinical
trials for a variety of reasons.19 Some possible reasons are financially
motivated; treating a patient through a clinical trial is usually more
expensive for the doctor's office.2° Clinical trials also require a heavy load
of paperwork and doctors may have greater worries about malpractice
litigation from patients in clinical trials.2
Furthermore, the costs in the United States associated with medical
labor and infrastructure are among the highest in the world. For U.S.
pharmaceutical companies, clinical trials currently account for around forty
14 See Patrick McGee, Clinical Trials on the Move: Dropping Enrollment for Clinical
Trials in the US and Western Europe Has Companies Looking to Countries Like India and
China as a Solution, DRUG DISCOVERY & DEV., June 1, 2006, at 16, available at 2006
WLNR 10305103.
IS See Samiran Nundy & Chandra M. Gulhati, A New Colonialism? - Conducting
Clinical Trials in India, 352 N. ENGL. J. MED. 1633, 1634 (2005), available at
http://content.nejm.org/cgi/reprint/352/16/1633.pdf
16 See Glenn McGee, Salt in the Wound: Will India Rise Up Against the Oppression of
Foreign Clinical Trials?, THE SCIENTIST, Apr. 1, 2006, at 26, available at http://www.the-
scientist.com/2006/4/1/26/1/.
17 See E.J. Mundell, Clinical Trials for Cancer Running Out of Volunteers, HEALTHDAY







percent of the total cost of developing a drug. 22 U.S. pharmaceutical
companies have a large incentive to find a more efficient and less costly
solution to the financial and logistical problems associated with conducting
trials in the United States.
An especially attractive solution for U.S. companies is the outsourcing
of clinical trials to India, because it offers relief for their logistical and
financial problems. Logistically, recruitment is faster and easier because
for many in India, the chance to participate in an investigational drug trial is
a healthcare windfall. 23 Financially, India provides a significant cost
advantage for U.S. and Western European pharmaceutical companies
because of its low-cost and English-speaking medical staff, large patient
traffic, good health infrastructure, and credible, established clinical research
organizations. 24 The New England Journal of Medicine reported that
outsourcing clinical trials to India can save U.S. pharmaceutical companies
up to sixty percent on the cost of the trials.25 India is the second most
populous country in the world, and another benefit to outsourcing drug
trials to India is access to the large, diverse, and drug-naYve patient
population. Drug naivety means that the patient has not previously taken
any medication for their condition. This is a positive point for those
conducting clinical trials because it lowers the chance of any unforeseen
drug interactions and also avoids the burden of switching a patient from
their current medication to the trial drug.
Companies that perform the clinical testing and then report the data to
pharmaceutical companies-clinical research organizations ("CROs")-
advertise an "Indian Advantage," touting the country's huge patient base,
diversity of diseases, drug-naYve population, and high trial enrollment
rates.26 For example, iGate Clinical Research International, an Indian CRO,
advertises on its commercial webpage that India represents a "largely,,27
untapped resource for clinical trials. This CRO advertises and estimates
India's diseased patient populations at "40 million asthmatic," "34 million
diabetic," "8-10 million people HIV positive," "3 million cancer patients,"
">2 million cardiac related deaths," "1.5 million patients with Alzheimer's
22 Nundy & Gulhati, supra note 15, at 1634.
23 See Kahn, supra note 6.
24 Gireesh Chandra Prasad & James Mathew, Doc India's Got a Cure for Global
Pharma, ECON. TIMES (India), Apr. 28, 2006, available at 2006 WLNR 7200824.
25 Nundy & Gulhati, supra note 15, at 1634 (citing Gunjan Sinha, Outsourcing Drug
Work: Pharmaceuticals Ship R&D and Clinical Trials to India, Sci. AM. ONLINE, Aug. 16,
2004, available at http://www.sciam.com/article.cfm?articlelD=00033282-DBF5-10F9-
975883414B7F0000).
26 See, e.g., iGATE Clinical Research International, Indian Advantage, http://www.
igatecr.com/company/indiaadvantage/index.php (last visited Nov. 25, 2007).
27 Id.
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disease," and "1% of population suffer from schizophrenia. 28
While it is getting harder to perform investigational trials in the United
States, the availability of a large and desirable pool of potential volunteers
as well as the reduced costs associated with labor and infrastructure in India
make outsourcing the trials to India an attractive solution.
B. Regulatory Changes
Two recent changes in Indian law have also fueled the outsourcing of
U.S. clinical work to India. One change was in Indian intellectual property
law, which expanded the scope of patentable subject matter in India to
include pharmaceutical products. A second change was in India's
regulations of clinical trials. The changes in Indian regulations complement
the United States regulatory scheme2 9 and work to drive the expansion of
outsourcing.
The change in Indian intellectual property law occurred in 2005 when
India amended its Patents Act to bring it into compliance with the World
Trade Organization's ("WTO") Trade Related Intellectual Property Rights
agreement ("TRIPS"). ° Article 27.1 of TRIPS requires member countries
to make patentable "any inventions, whether products or processes, in all
fields of technology . ,,3 Furthermore, Article 39.3 requires protection
of data acquired in clinical trials against any "unfair commercial use."32
Prior to the amendments, India did not allow patents on pharmaceutical
products, thus discouraging foreign companies from entering India out of
fear that their products would be reverse-engineered and generically mass
manufactured. The new intellectual proper3 protections will undoubtedly
encourage outsourcing clinical trials to India.3
Second, the Indian government also made important changes in its
regulations regarding clinical trials. The Indian regulations affecting new
28 Id.
29 U.S. regulations, discussed infra Part III, permit data from foreign clinical studies to be
used in an application for the marketing approval of a new drug. See 21 C.F.R. § 314.106
(2005) (explaining the acceptance of an application when it is solely supported by foreign
clinical data); 21 C.F.R. § 312.120 (2005) (explaining the acceptance of foreign clinical data
generally).
30 See The Patents (Amendment) Act, No. 15 of 2005; India Code (2005), available at
http://lawmin.nic.in/patentsact2005.pdf.
31 Agreement on Trade-Related Aspects of Intellectual Property Rights art. 27.1, Apr. 15,
1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, Legal
Instruments-Results of the Uruguay Round, 33 I.L.M. 1197 (1994) [hereinafter TRIPS],
available at http://www.wto.org/english/docs e/legal-e/27-trips.pdf.
32 Id. art. 39.3.
33 See Laura Thomson, Changing Times for Patenting in India, KNOWLEDGELrNK




drugs and clinical trial are found in Schedule Y of the Indian Drugs and
Cosmetics Rules. 34 In January 2005, the Indian government changed
Schedule Y and removed a "phase lag," allowing foreign pharmaceutical
companies to perform trials of new drugs in India at the same time as trials
of the same phase in other countries.3 The "phase lag" rule had required
that a trial of a drug not discovered in India must have already occurred in
another country. For example, such a drug could not be tested in a Phase II
trial in India unless it had already been tested in a Phase 1I trial elsewhere.
The rule's purpose had been "to protect Indians from being used as guinea
pigs in the testing of unproved drugs of foreign origin."
36
The regulatory scheme in the United States complements the changes
made in India, because it allows for the drugs to be approved for sale based
on data from foreign clinical trials.37 Under Section 314.106(b)(1) of Title
21 of the Code of Federal Regulations, an application to market a new drug
under an investigational new drug application ("IND") may be approved by
the FDA even if such application is based only on data from foreign clinical
trials, as long as the following three requirements are met:
(1) the data are applicable to the U.S. population and medical practice;
(2) the clinical investigators are of recognized competence; and
(3) the data "may be considered valid without the need for an on-site
inspection by FDA or, if FDA considers such an inspection to be
necessary, FDA is able to validate the data through an on-site
inspection or other appropriate means. 38
The FDA will also accept research for foreign clinical studies not conducted
under an IND.39 Such studies are accepted if they are "well designed, well
conducted, performed by qualified investigators, and conducted in
accordance with ethical principles acceptable to the world community. 4 °
By mentioning "ethical principles acceptable to the world community," the
regulation is referring to Helsinki V of the Declaration of Helsinki,
discussed below in Part V.A. The broad wording and the inclusion of an
out-of-date international document in the regulations regarding acceptance
of foreign clinical trials allow many U.S. pharmaceutical companies to
outsource their clinical trials abroad.
In summary, the changes in Indian intellectual property law and the
34 The Drugs and Cosmetics Rules, 1945 (as Amended up to the June 30th, 2005)
[hereinafter Drug and Cosmetics], available at http://cdsco.nic.in/html/Drugs&CosmeticAct
.pdf.
35 Nundy & Gulhati, supra note 15, at 1633.
36 Id. at 1634.
" See 21 C.F.R. § 314.106(b)(1) (2003).
38 id.
" See id. § 312.120.
40 Id. § 312.120(a).
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removal of the "phase lag" in clinical trial regulations complement the
regulatory scheme in the United States, and have fueled the outsourcing
boom by expanding the number of trials that may be performed and
allowing the most cutting-edge clinical drug research to be conducted in
India.
III. REGULATION OF CLINICAL TRIALS AND THE PROTECTION
OF TEST SUBJECTS UNDER UNITED STATES LAW
A. Regulation of Clinical Trials
The United States Food and Drug Administration ("FDA") regulates
clinical trials in the United States. 41 Before starting a clinical trial, a
sponsor submits an IND to the FDA.42 Generally, an IND must include
information in three broad areas:
(1) Animal pharmacology and toxicology studies to permit an
assessment of whether the product is reasonably safe for initial
testing in humans;
(2) Manufacturing information to ensure that the company can
consistently and adequately supply batches of the drug; and
(3) Clinical protocols and investigator information to assess whether
the investigators are qualified to conduct the trials and assess the
potential risks to which the human test subjects will be exposed.43
The IND must also specify an Institutional Review Board ("IRB") to
supervise the clinical research done under the IND.44  The IRB is the
responsible party to ensure that the clinical trials are properly set out to
protect the welfare and rights of the human test subjects. 5 An IRB may be
"any board, committee, or other group formally designated by an institution
to review, to approve the initiation of, and to conduct periodic review of,
biomedical research involving human subjects. The primary purpose of
such review is to assure the protection of the rights and welfare of the
human subjects.
4 6
After an IND submission, the FDA will evaluate the application and
41 Statutory authority is found mainly in the Federal Food, Drug and Cosmetic Act. See
21 U.S.C. § 301 (2005).
42 See 21 C.F.R. § 312 (2005).
43 Areta L. Kupchyk & Josephine M. Torrente, R&D 101: Legal Issues During Research
and Development, 878 PLI/PAT 9, 18 (2006).
44 See 21 C.F.R. § 56 (2005).
41 See id.
46 21 C.F.R. § 56.102(g) (2005). FDA regulations further require that an IRB consists of
at least five experts and lay people who have different backgrounds, experience, and
expertise "to ensure a complete and adequate review of research activities." Kupchyk &
Torrente, supra note 43, at 19.
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determine within thirty days whether there are any issues that should
prevent the study from going forward. 47  Under the law there is no
requirement that the FDA inform the sponsor of the IND of an approval. 8
Therefore, if the sponsor has heard nothing from the FDA regarding the
IND submission on day 31 after the submission, the study may proceed as
described in the IND.49 However, if the FDA has any concerns with the
IND then it may issue a "clinical hold.",
50
A clinical hold is an administrative order from the FDA to delay or
suspend the study.51 When a clinical hold is imposed on a proposed study,
the hold prohibits the sponsor from giving the investigational drug to test
subjects and also prohibits the recruitment of any new test subject.52 The
sponsor must address the issues related to a clinical hold by submitting a
response to the FDA.53 The clinical hold will be removed if the sponsor
adequately resolves the issues and, again, the FDA will review the
sponsor's response within thirty days and notify the sponsor of its
decision.54
Under an IND, there are three phases (I, II, and III) for clinical
research on drugs for humans.55 In general the phases are thought of as
sequential but there may be some overlap between consecutive phases.56
Phase I is the introduction of the investigational drug into human test
subjects and is used to evaluate drug metabolism, structure-activity
relationships, the pharmacological mechanism of action, and the side effects
associated with increasing doses.57 Typically, Phase I trials involve a small
number (approximately twenty to eighty) of healthy volunteers or patients.
58
The data obtained from the Phase I trials assists in the design of Phase II
studies.
Phase II studies are used to obtain data on the effectiveness of the drug
on treatment of patients with the disease or condition the drug is meant to
combat.59 Phase II studies typically involve a larger number of participants
47 See 21 C.F.R. § 312.20 (2005).
48 Kupchyk & Torrente, supra note 43, at 19.
49 id.




54 Kupchyk & Torrente, supra note 43, at 20.
55 See Frequently Asked Questions on Drug Development and Investigational New Drug
Applications, http://www.fda.gov/cder/about/smallbiz/faq.htm (last visited Nov. 26, 2007)
(hereinafter FAQ on Drug Development].
56 id.
57 Kupchyk & Torrente, supra note 43, at 21.
58 Id.
59 FAQ on Drug Development, supra note 55.
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(several hundred patients) and also help to determine short-term side effects
and risks of taking the investigational drug. 60 The information obtained
from the Phase II trials may lead to the final and largest phase, Phase III.
Phase III clinical trials are intended to obtain data on the effectiveness
and safety on the widespread use of the drug so that an overall benefit-risk
relationship of the drug may be assessed.6' Phase III studies must provide
an adequate basis to extrapolate results from the tested population of
patients for application to the general population. The results of Phase III
trials determine whether there is enough evidence of efficacy in treating the
disease or condition needed for approval of the investigational drug by the
FDA.62 The data obtained in Phase III studies are also used by the FDA in
determining proper physician labeling. 63 Typically, Phase III studies
include several thousand people. 64
However, the FDA will also accept research from foreign clinical
studies not conducted under an IND.65 Such studies are accepted if they are
"well designed, well conducted, performed by qualified investigators, and
conducted in accordance with ethical principles acceptable to the world
community., 66 Thus, regulations in the United States will allow approval
of an investigational drug even if all the clinical data were acquired using
patients in India.
B. Protecting Test Subjects
Federal regulations protecting human test subjects in investigational
drugs trials are found in the Federal Food, Drug and Cosmetic Act. 67 The
FDA regulations for human clinical trials are mostly codified in Title 21 in
the Code of Federal Regulations, Parts 50, 54 and 56.68 The FDA
regulations apply to all clinical trials for new dru s under Sections 505(i)
and 505(g) of the Food, Drug and Cosmetic Act. Named "Protection of
60 Id.
61 Kupchyk & Torrente, supra note 43, at 21.
62 Id.
63 Id.
64 FAQ on Drug Development, supra note 55.
65 See 21 C.F.R. § 312.120 (2005).
66 Id. § 312.120(a).
67 See Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 301 (2005).
68 See 21 C.F.R. § 50 (2005); 21 C.F.R. § 54 (2005); 21 C.F.R. § 56 (2005). Other FDA
regulations do relate to clinical trials and human research subjects, such as 21 C.F.R. § 312
(regulating IND applications); 21 C.F.R. § 314 (regarding FDA approval to market a new
drug). These regulations are related to the conditions set forth in 21 C.F.R. §§ 50, 54, and 56
to FDA authorization of applications for investigational and new drug activities.
69 Section 505(i) in the Federal Food, Drug and Cosmetic Act is Title 21 of the United
States Code Section 355(i). 21 U.S.C. § 355(i) (2005). Section 505(g) of the Act is Title 21
of the United States Code Section 355(g). 21 U.S.C § 355(g) (2005).
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Human Subjects," Part 50 of the regulations requires informed consent and
additional safeguards regarding research on children.70 Part 56 of the
regulations, "Institutional Review Boards," puts forth the general standards
for the composition, operation, and responsibility of IRBs, mentioned in
Part III.A, above, which oversee clinical trials. 7' By periodic reviews both
before and during the clinical testing, IRBs serve to assure that adequate
actions are taken to protect the rights and welfare of humans participating
as subjects in clinical research.7
Part 50 of the regulations sets forth the requirements for informed
73consent. Part 50.25 enumerates eight elements that must be explained to a
volunteer before receiving an informed consent: (1) the purposes, duration
and procedure of the research; (2) reasonably foreseeable risks; (3) benefits
subject may reasonably expect; (4) alternative treatments that may be
advantageous to subject; (5) extent of confidentiality; (6) whether
compensation or medical treatments are available if injury occurs (for
research involving "more than minimal risk"); (7) whom to contact with
questions; and (8) voluntary nature of participation. 4 Part 50.27 also
requires that the informed consent be documented in a written agreement.75
Part 56, regulating IRBs, contains even more regulations that provide a
greater level of protection to human test subjects. In order to approve
clinical research, an IRB is required under Part 56.111 to determine that
seven elements related to the clinical trial are satisfied.76 They are:
(1) The risks to subjects are minimized by using sound research
procedures and, if appropriate, by using procedures already being
performed on the subject;
(2) The risks to subject are reasonable in comparison to the
anticipated benefits and knowledge that may be expected from the
research;
77
(3) The selection of subjects is "equitable" ;78
(4) Informed consent is required for each subject;
79
70 21 C.F.R. § 50 (2005).
71 Id. § 56.
72 FAQ on Drug Development, supra note 55.
71 See 21 C.F.R. § 50.
74 Id. § 50.25.
75 Id. § 50.27.
761Id. § 56.111.
77 The regulation also mentions that IRBs should "not consider possible long-range
effects of applying knowledge gained in the research." Id. § 56.11 l(a)(2).
78 "In making this assessment the IRB should take into account the purposes of the
research and the setting in which the research will be conducted and should be particularly
cognizant of the special problems of research involving vulnerable populations, such as
children, prisoners, pregnant women, handicapped, or mentally disabled persons, or
economically or educationally disadvantaged persons." Id. § 56.11 l(a)(3).
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(5) Informed consent must be documented;
80
(6) The research plan has a provision to monitor the safety of subjects,
where appropriate; and
(7) The research plan has adequate provisions to protect the privacy of
the subject.81
Also importantly, in the case when some or all of the test subjects are from
vulnerable populations, such as being educationally or economically
disadvantaged, the regulation explicitly requires that "additional
safeguards" are present in the study "to protect the rights and welfare of
these subjects.",
8p
Overall, U.S. law offers many protections for the test subjects,
including the informed consent requirement and special consideration for
vulnerable populations. This Comment now turns to an explanation of the
counterpart regulations and protections under Indian law and a comparison
between India and the United States in this area.
IV. REGULATION OF CLINICAL TRIALS AND THE PROTECTION
OF TEST SUBJECTS UNDER INDIAN LAW
A. Regulation of Clinical Trials
The Indian regulations for clinical trials are found in Schedule Y of the
Indian Drugs and Cosmetics Rules. 3 The regulations in India are similar in
many ways to those in the United States.
Before starting a clinical trial, a foreign sponsor must get permission
84
from the Indian government and an institutional ethics committee. An
ethics committee must be responsible for each site where the trial will
occur.85 The ethics committee must consist of seven or more members.86
Members should be "a mix of medical/non-medical, scientific and non-
scientific persons, including lay public, to reflect the different
viewpoints."
87
Permission is obtained by submitting proper forms and information to
the government and institutional ethics committee. 88 Generally, the
79 The requirement is according to the regulations in Part 50.
80 The documentation must be in accord with the regulations in Part 50.27.
81 21 C.F.R. § 56.111.
82 id.
83 Drug and Cosmetics, supra note 34, Schedule Y.
84 Id. art. 2(1)(i).
85 Id. apx. VIII, item 1.
86 Id.
87 id.
88 Id. art. 1.
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information is in three areas: (1) animal pharmacology and toxicology
studies, (2) manufacturing information, and (3) clinical data from Phase I
trials (even after the change in "phase lag" rule, Indian law still does not
allow Phase I trials of drugs not discovered in India). Furthermore, the
Indian government requires information on the regulatory status of the new
drug in other countries. 89 However, unlike the U.S. regulations, the Indian
statutes do not require submitting detailed clinical protocols to the
government; this is left to the evaluation by an institutional ethics
committee. 90
The institutional ethics committee under the Indian regulations is
similar in structure and function to the IRBs under the U.S. regulations.
Like an IRB, the ethics committee becomes the responsible party in regards
to making sure that the clinical protocols are properly set out and the
welfare and rights of the human test subjects are protected. 9'
The Indian regulations recognize four phases (I, II, III, and IV) of
clinical research on humans. 92 For all practical purposes the first three
phases are the same as in the U.S. regulations. The Indian regulations have
added Phase IV trials named "Post Marketing Trials," which are optimizing
trials performed after the approval and include additional drug-drug
interaction, dose-response, or safety studies to "support use under the
approved indication(s). 93
Overall, it can be said that the regulation of clinical trials in India and
the United States are similar. Both require a governmental approval before
a clinical trial may occur. The most important similarity is the existence of
the third party reviewers: the IRBs in the United States and the institutional
ethics committees in India. However, the Indian scheme tends to delegate
more oversight of the trials from the government to the institutional ethics
committee. Specifically, the institutional ethics committees in India are the
only parties that review the detailed protocols and assess the risk of an
investigational trial on test patients. In the United States, both the FDA and
the IRBs assess the protocols and risks. Despite some minor differences in
the details, the overall regulatory systems in India are similar to the United
States when U.S. pharmaceutical companies outsource clinical trials to
India.
B. Protecting Test Subjects
Indian regulations to protect human test subjects are also found in
89 Drug and Cosmetics, supra note 34, Schedule Y, art. l(1)(v).
90 See id. art. 2(5).
91 Id.
92 Id. art. 2(6)-(9).
9' Id. art. 2(9).
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Schedule Y of the Indian Drugs and Cosmetics Rules. 94 The Drug and
Cosmetics Rules require informed consent by the test subjects and call for
extra protection when certain classes of patients are subject to trial. 95 The
laws also place requirements on the composition, operation, and
responsibility of the institutional ethics committees that are responsible for
ensuring the protection of test subjects.96
Appendix V of Schedule Y in the Rules sets forth the essential
elements of informed consent.97 The law enumerates fourteen elements that
are essential to the test subject's informed consent (compared to eight
elements in the U.S. system): (1) statement of the purpose of the research;
(2) anticipated duration of volunteer's participation; (3) the procedures
and/or protocol to be followed; (4) reasonably foreseeable risks or
discomforts; (5) benefits the volunteer may reasonably expect; 98 (6)
disclosure of specific appropriate alternative procedures or therapies
available; (7) extent of confidentiality; (8) trial treatment schedule and the
probability for random assignment to each treatment (for randomized
trials); (9) compensation and/or treatment(s) available in case of
investigation-related injury; (10) whom to contact with any questions
related to the investigation; (11) anticipated payment, if any, to the
volunteer for participating; (12) description of volunteer's responsibilities;
(13) statement that "participation is voluntary, that the subject can withdraw
from the study at any time and that refusal to participate will not involve
any penalty or loss of benefits"; and (14) any other relevant information.99
As in the United States, the regulations require that the informed consent be
in a written agreement that was freely entered into. 00 Although enumerated
differently, there are no major differences between the required elements of
informed consent in India and those under U.S. law.
Appendix VIII provides certain requirements for the composition,
operation, and responsibility of the institutional ethics committees.'01 The
institutional ethics committees assure, by ongoing periodic review both
before and during the clinical testing, that the rights, safety, and well-being
of test subjects are protected.10 2 Under Indian law, the ethics committee
guarantees that the research is conducted in accordance with the Declaration
94 Drug and Cosmetics, supra note 34, Schedule Y.
9' Id. art. 2(4) & (5) (describing generally the requirement of informed consent and the
responsibilities of the ethics committee).
96 See id. apx. VIII (discussing requirements related to the institutional ethics
committees).
97 Id. apx. V, item 1.
98 Id. ("If no benefit is expected subject should be made aware of this.").
99 Id.
10o Drug and Cosmetics, supra note 34, Schedule Y, art. 2(4)(i).
1o1 See id. apx. VIII.
102 Id. art. 2(5).
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of Helsinki. 10 3 Unlike the U.S. regulations, 0 4 Indian law refers to the most
current Declaration and an outdated version of the Declaration of Helsinki
is not codified into law.
V. THE PROTECTION OF TEST SUBJECTS UNDER
INTERNATIONAL LAW
The most general of international standards related to human
experimentation is stated in Article 7 of the International Covenant on Civil
Political Rights ("ICCPR"): "[N]o one shall be subjected without his free
consent to medical or scientific experimentation." 05 In addition to this
general declaration from the United Nations, there are additional
international documents that more closely address human experimentation.
The Declaration of Helsinki and the Nuremberg Code are the most relevant
to this Comment and are discussed next.
A. The Declaration of Helsinki
The Declaration of Helsinki, mentioned in both Indian'
0 6 and U.S. 10 7
regulations, is the most relevant international document to this comment.
The World Medical Association ("WMA") endorsed its first document on
human experimentation in 1964, known as the Declaration of Helsinki.
10 8
The Declaration of Helsinki is a statement of ethical principles that offers
guidance to participants in medical research involving human subjects.'0 9
The Declaration has been amended five times-in 1975, 1983, 1989, 1996,
and 2000.110 Notes of clarification were added in 2002 and in 2004. l '
1. Helsinki VI
The newest version of the Declaration is the version amended in 2000,
Helsinki VI. 112 This is the version applicable to Indian trials, while U.S.
103 Id. apx. II, item 6. The Declaration of Helsinki is an international agreement and is
discussed infra Part V.
104 See 21 C.F.R. § 312.120(c)(4) (2005).
105 International Covenant on Civil and Political Rights, G.A. Res. 2200A (XXI), art. 7,
U.N. Doc. A/6316 (Dec. 19, 1966).
106 Drug and Cosmetics, supra note 34, Schedule Y, apx. II, item 6.
107 21 C.F.R. § 312.120(c)(4).
108 WORLD MEDICAL ASSOCIATION, DECLARATION OF HELSINKI: ETHICAL PRINCIPLES FOR
MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (1964) [hereinafter HELSINKI], available
at http://www.wma.net /e/policy/pdf/1 7c.pdf.
109 Medical research involving human subjects, as defined in the Declaration, includes
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law relies on the earlier version, Helsinki V. Helsinki VI begins with a
nine-provision introduction that recognizes the conflict between the
physician's duty to serve the best interests of his/her patient and the need to
expose test subjects to risks in the pursuit of medical advancement. 1 3 The
well-being of an individual test subject is most important; it is stated in the
declaration that "[m]edical progress is based on research which ultimately
must rest in part on experimentation involving human subjects" and "[i]n
medical research on human subjects, considerations related to the well-
being of the human subject should take precedence over the interests of
science and society." ' 14 Furthermore, in Provision 8 of the Introduction, the
Declaration acknowledges that some research populations, particularly the
economically and medically disadvantaged, are especially vulnerable to
unethical treatment and require special protection:
Medical research is subject to ethical standards that promote respect
for all human beings and protect their health and rights. Some
research populations are vulnerable and need special protection. The
particular needs of the economically and medically disadvantaged
must be recognized. Special attention is also required for those who
cannot give or refuse consent for themselves, for those who may be
subject to giving consent under duress, for those who will not benefit
personally from the research and for those for whom the research is
combined with care.
115
Section B of the Declaration sets out basic principles for all medical
research.1 16 Provision 19 in Section B is relevant to outsourcing of clinical
trials from developed countries into developing countries and states:
"Medical research is only justified if there is a reasonable likelihood that
the populations in which the research is carried out stand to benefit from the
results of the research."
' 1 7
The final section, Section C, states additional provisions necessary
when research is combined with medical care. 1 8 Of particular interest is
Provision 30, stating "[a]t the conclusion of the study, every patient entered
into the study should be assured of access to the best proven prophylactic,
diagnostic and therapeutic methods identified by the study." 1 9 Provision
30 has been subject to criticism for being impractical and it is also thought
to place too heavy a burden on research institutions as well as to create
..3 See id. at 1-2.
114 HELSINKI, supra note 108, at 1.
115 Id. at 2.
116 See id. at 2-4.
117 Id. at 3.




undue incentives to participate in a clinical trial. 120 However, the WMA
General Assembly has not chosen to amend the provision. Rather, in 2004,
the Assembly added a note of clarification to the Declaration in regards to
Provision 30, stating:
The WMA hereby reaffirms its position that it is necessary during
the study planning process to identify post-trial access by study
participants to prophylactic, diagnostic and therapeutic procedures
identified as beneficial in the study or access to other appropriate
care. Post-trial access arrangements or other care must be described
in the study protocol so the ethical review committee may consider
such arrangements during its review.
12 1
Overall, the current version of the Declaration of Helsinki offers a
fairly detailed and comprehensive set of rules and standards to protect test
subjects. The document offers stronger protections than either of the
codified laws in the United States and India and is particularly applicable to
the situation relevant in this comment: outsourcing clinical trials to
developing countries.
2. Helsinki VIApplied to Indian Trials
As stated in Helsinki VI Provision 8, special consideration needs to be
made in performing clinical trials on economically and medically
disadvantaged populations. 
122
Special considerations may be necessary to ensure that informed
consent is "freely given" in India. For example, economically
disadvantaged Indians may receive more money per month to participate in
a trial than they could earn working their jobs. 123 For Indians without
access to health care, the chance to participate in a clinical trial may amount
to a healthcare windfall. For example, in one Indian trial outsourced by the
German drug maker Boeringer Ingelheim, every test subject received free
routine medical checkups during the course of the study. 124 The doctor's
offices and hospitals also stand to gain a relatively large amount of money.
In the same Boeringer Ingelheim trial, each participating hospital or office
would receive 30,000 rupees ($675) from the drug company for each
120 See WORLD MEDICAL ASSOCIATION, WORKGROUP REPORT ON THE REVISION OF
PARAGRAPH 30 OF THE DECLARATION OF HELSINKI (2004), available at http://www.wma.net
/e/ethicsunit/pdf/wg-doh-jan2004.pdf.
121 HELSINKI, supra note 108, at 5.
122 Id. at 2.
123 Nundy & Gulhati, supra note 15, at 1634.
124 India: Test Bed for Drugmakers, PHARMA MARKETLETTER, Mar. 6, 2006, available at
2006 WLNR 3820168.
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patient signed up for the trial. 125 The enticement of medically
disadvantaged volunteers with health care checkups and drugs that are
worth more than their annual salary, as well as relatively large amounts of
money given directly to hospitals, may trigger the need for additional
safeguards to ensure that informed consent takes place under the
Declaration of Helsinki.1
26
Provisions 19 and 30 of the Declaration also present interesting points
of conflict in the realm of outsourced clinical trials. Provision 19 would
require that the population tested-most likely impoverished Indians-
benefit from the results of the research. 127 Similarly, Provision 30 would
require that successful drugs tested on Indian clinical subjects be made
accessible to them after the trials. 128 However, reality calls into question
exactly what level of affordability is required for "access" to the new drugs.
That is, the price on most drugs tested on Indians will end up being so high
that most of the Indian population will not be able to afford them. For
example, Eli Lilly plans to price just one 10-mg tablet of tadalafil, known
by its trademark name Cialis, "at $9 (400 rupees) which is equivalent to
four days' wages for a well-paid manual worker [in India]."'' 2 9
3. Helsinki V." United States Law
For FDA approval of a clinical study not conducted under an IND, it is
important to consider not the newest version of the Declaration of Helsinki
("Helsinki VI") but rather Helsinki V, the version preceding the
amendments in 2000. Helsinki V is important because it is codified in Part
312 of Title 21 of the Code of Federal Regulations. 130 For the FDA to
accept foreign clinical studies not conducted under an IND, "[f]oreign
clinical research is required to have been conducted in accordance with the
ethical principles stated in the 'Declaration of Helsinki' . . . or the laws and
regulations of the country in which the research was conducted, whichever
represents the greater protection of the individual.' 13 1 The regulation refers
to the "Declaration of Helsinki" as reproduced in Title 21 of the Code of
Federal Regulations Section 312.120(c)(4). 132 The version of the
Declaration in the Code of Federal Regulations is Helsinki V, rather than
125 Id.
126 See HELSINKI, supra note 108, at 5.
127 See id. at 2.
128 See id. at 4.
129 Nundy & Gulhati, supra note 15, at 1635 (citing James Mathew, Eli Lilly gets EMR
for Week-end Pill Cialis, ECONOMIC TIMES (India), Sept. 16, 2004, at 11).
130 Foreign Clinical Studies Not Conducted Under an IND, 21 C.F.R. § 312.120 (2005).
131 Id. § 312.120(c)(1).
132 Id. § 312.120(c)(4).
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the more recent Helsinki VI.' 33 The FDA is aware of the amendments to
the Declaration of Helsinki but it has taken no action to incorporate the
newest version of the Declaration into its regulations. 134 Specifically, the
FDA provides guidance that "the action of the World Medical Association
[in making the amendments in 2000] did not change FDA regulations.
135
There are significant differences between Helsinki V codified in the
FDA regulations and the most recent version released by the WMA. Highly
relevant to the subject matter of this Comment, Provision 8 in Helsinki V
does not mention a need for special consideration of ethical issues when
testing on economically or medically disadvantaged populations. 136
Furthermore, in Helsinki V there is no requirement the population involved
in the experiments benefit from the results of the research. 137 Also unlike
the newest version, Helsinki V does not require that successful drugs be
made accessible after the trials to the participants.1 38 These differences are
particularly relevant to research outsourced by U.S. pharmaceutical
companies to India, because, in India, the institutional ethics committees
must hold the clinical trials to the standards of the newest version of the
Declaration. However, in the United States a trial not conducted under an
IND only has to conform to Helsinki V for acceptance by the FDA.
B. The Nuremberg Code
During World War II, Nazi physicians and scientists committed
atrocious crimes by performing medical and drug research on unwilling test
subjects, who were primarily held at concentration camps. 139 Following the
war, twenty-three physicians and scientists who had performed this research
133 See HELSINKI, supra note 108, at 5 (Helsinki VI, amended in 2000); Cf 21 C.F.R §
312.120(c)(4) (Helsinki V, last amended in 1989).
134 See FOOD AND DRUG ADMINISTRATION, GUIDANCE FOR INDUSTRY: ACCEPTANCE OF
FOREIGN CLINICAL STUDIES 2 (2001), available at http://www.fda.gov/ohrms/dockets/98fr
/010079g2.pdf ("In October 2000, the World Medical Association revised the Declaration.
FDA has not taken action to incorporate those revisions into its regulations. FDA is making
available this guidance document to clarify that the action of the World Medical Association
did not change FDA regulations").
135 Id.
136 See 21 C.F.R. § 312.120(c)(4) (2005). Absent in Helsinki V, the requirement of
special consideration for economically or medically disadvantaged populations is found in
Provision 19 of Helsinki VI. See HELSINKI, supra note 108, at 4 (Helsinki VI, amended in
2000).
137 See id.
138 See id. This requirement could be found in Provision 30 of Helsinki VI. See
HELSINKI, supra note 108, at 5 (Helsinki VI, amended in 2000).
139 See generally Rebecca A. Finkenbinder, Comment, New Recommendations on
International Human Research: Can Minimum Standards Prevent the Exploitation of
Vulnerable Human Subjects in Developing Countries?, 21 PENN ST. INT'L L. REv. 363, 371-
72 (2003).
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were charged with war crimes' and crimes against humanity before a
military tribunal of American judges in what has been called the "Doctors'
Trial" in Nuremberg, Germany (1946-1947).40 The trials ended with the
conviction of fifteen of the defendants and, as a part of the final judgments,
the judges included a set of conditions to govern the practice of medical
experimentation on humans now known as the "Nuremberg Code."'
141
The Nuremberg Code enumerates ten provisions meant to govern
medical experimentation performed on human subjects. The first of the ten
provisions begins with a strong assertion: "[t]he voluntary consent of the
human subject is absolutely essential."'' 42 This means that the volunteer
must "have the legal capacity to give consent; should be so situated as to be
able to exercise free power of choice, without the intervention of any
element of force, fraud, deceit, duress, over-reaching, or other ulterior form
of constraint or coercion ....,,43 The other provisions in the Nuremberg
Code deal mainly with assurances that the experiments are based on the
scientific method and ethically responsible in design.
44
Unlike the FDA regulations and the Declaration of Helsinki, the
Nuremberg Code does not require that research be monitored and approved
by an independent party. Also unlike the FDA regulations and the
Declaration of Helsinki, the provisions in the Nuremberg Code are directed
at scientists rather than institutions. In regard to the voluntary consent, the
Nuremberg Code places the duty solely on the scientists, stating "[t]he duty
and responsibility for ascertaining the quality of the consent rests upon each
individual who initiates, directs or engages in the experiment. It is a
personal duty and responsibility which may not be delegated to another
with impunity." 45 The Nuremberg Code is not specifically adopted by
either the FDA or the Indian government and, therefore, it is generally not a
legally binding force. However, it was the first international legal
document relating to human experimentation and has clearly been
influential in the drafting of future regulations in both countries.
140Id. at 371.
141 The Nuremberg Code, in 2 TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG
MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAW No. 10, at 181-82 (U.S. Gov't




144 For example, Provision 2 states that all experiments should "yield fruitful results for
the good of society" and not be "random and unnecessary in nature." Id. Also, Provision 4






India has positioned itself to maximize the value of its unique
resources: the large and diverse patient population, the developed medical
infrastructure and the well-trained, inexpensive, and English-speaking
medical professionals. In modifying its intellectual property laws and its
regulation of clinical trials, the Indian government has taken steps to protect
foreign investment in clinical trials as well as the rights and safety of Indian
trial volunteers. The country seeks to capture a share of the value it adds to
the U.S. pharmaceutical companies' research and development models.
Also, for many diseased Indians, the chance to participate in an
investigational trial is a healthcare windfall, because these patients may
otherwise have received no health care services. India is poised to make
significant gains as a result of the upcoming boom in outsourcing clinical
trials, and U.S. companies (and ultimately the consumers) also stand to gain
as such outsourcing provides a more cost-effective solution to their drug
development activities.
Outsourcing clinical research to India is not a story of profit-driven
U.S. companies pushing unproven pharmaceuticals into India's highly
vulnerable test subjects. U.S. companies do not escape their obligations to
protect the trial test subjects in India that would be required if such trial was
conducted domestically. In fact, the regulations in India are arguably more
pro-patient than in the United States as witnessed by the acceptance of the
newest version of the Declaration of Helsinki under Indian law while the
U.S. government only recognizes the outdated 1989 version of the
Declaration. Still, there is a legitimate concern over the Indian
government's enforcement of its own regulations and the oversight of the
ethics committees. 146 As India has acted to maximize the value of its
unique resources, it must also leverage them to force U.S. companies to
comply with the most current international ethical standards and all Indian
regulations.
146 See Nundy & Gulhati, supra note 15, at 1635.
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